Journal
DRUGS OF THE FUTURE
Volume 35, Issue 3, Pages 197-217Publisher
PROUS SCIENCE, SAU-THOMSON REUTERS
DOI: 10.1358/dof.2010.035.03.1452077
Keywords
-
Categories
Funding
- National Institutes of Health [CA096984]
- Maryland Industrial Partnership [4225]
- NATIONAL CANCER INSTITUTE [R01CA096984] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Acquired drug resistance to mycotic infections is rapidly emerging as a major medical problem. Opportunistic fungal infections create therapeutic challenges, particularly in high-risk immunocompromised patients with AIDS, cancel; and those undergoing transplantation. Higher mortality and/or morbidity rotes due to invasive mycosis have been increasing over the last 20 years, and in light of growing resistance to commonly used antibiotics, novel antifungal drugs and approaches are required. Currently, there is considerable interest in antifungal peptides that are ubiquitous in plant and animal kingdoms. These small cationic peptides may have specific targets or may be multifunctional in their mechanism of action. On the basis of recent advances in protein engineering and solid-phase syntheses, the utility and potential of selected peptides as efficient antifungal drugs with acceptable toxicity profiles are being realized. This review will discuss recent advances in peptide therapy for opportunistic fungal infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available